Late medical versus interventional therapy for stable ST-segment elevation myocardial infarction

Nature Clinical Practice Cardiovascular Medicine

Volumn 5, Issue 1, 2008, Pages 42-52

  Elmariah, Sammy ^a   Smith Jr , Sidney C ^b   Fuster, Valentin ^c  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE; ALTEPLASE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; NITRATE; OXYGEN; PLACEBO; STREPTOKINASE;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY STENT; DRUG MECHANISM; DRUG MEGADOSE; EXERCISE TEST; FIBRINOLYTIC THERAPY; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; MONOTHERAPY; MORBIDITY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REPERFUSION; REVIEW; RISK MANAGEMENT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ST SEGMENT ELEVATION; SYMPTOMATOLOGY; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT INDICATION;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BIOLOGICAL MARKERS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; EXERCISE TEST; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; MYOCARDIUM; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; STENTS; STROKE VOLUME; THROMBOLYTIC THERAPY; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 37849043197     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio1056     Document Type: Review

References (74)

1. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group (1994) Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 343: 311-322
2. Newby LK et al. (1996) Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. J Am Coll Cardiol 27: 1646-1655
3. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988) Randomised trial of
4. Horie H et al. (1998) Long-term beneficial effect of late reperfusion for acute anterior myocardial infarction with percutaneous transluminal coronary angioplasty. Circulation 98: 2377-2382
5. Pizzetti G et al. (1996) Coronary recanalization by elective angioplasty prevents ventricular dilation after anterior myocardial infarction. J Am Coll Cardiol 28: 837-845
6. Steg PG et al. (2004) DECOPI (DEsobstruction COronaire en Post-Infarctus): A randomized multi-centre trial of occluded artery angioplasty after acute myocardial infarction. Eur Heart J 25 2187-2194
7. Yousef ZR et al. (2002) Late intervention after anterior myocardial infarction: Effects on left venticular size, function, quality of life, and exercise tolerance: Results of the Open Artery Trial (TOAT Study). J Am Coll Cardiol 40: 869-876
8. Dzavik V et al. (2006) Randomized trial of percutaneous coronary intervention for subacute infarct-related coronary artery occlusion to achieve long-term patency and improve ventricular function: The Total Occlusion Study of Canada (TOSCA)-2 trial. Circulation 114: 2449-2457
9. Hochman JS et al. (2006) Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med 355: 2395-2407
10. Reimer KA et al. (1993) Reperfusion in acute myocardial infarction: Effect of timing and modulating factors in experimental models. Am J Cardiol 72: 13G-21G
11. [No authors listed] (1993) Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 342: 759-766
12. EMERAS (Estudio Multicentrico Estreptoquinasa Republicas de America del Sur) Collaborative Group (1993) Randomised trial of late thrombolysis in patients with suspected acute myocardial infarction. Lancet 342 767-772
13. Sadanandan S and Hochman JS (2000) Early reperfusion, late reperfusion, and the open artery hypothesis: An overview. Prog Cardiovasc Dis 42: 397-404
14. Sabia PJ et al. (1992) An association between collateral blood flow and myocardial viability in patients with recent myocardial infarction. N Engl J Med 327: 1825-1831
15. Hochman JS and Choo H (1987) Limitation of myocardial infarct expansion by reperfusion independent of myocardial salvage. Circulation 75: 299-306
16. Yousef ZR and Marber MS (2000) The open artery hypothesis: Potential mechanisms of action. Prog Cardiovasc Dis 42: 419-438
17. Roberts CS et al. (1983) Effect of coronary reperfusion on myocardial hemorrhage and infarct healing. Am J Cardiol 52: 610-614
18. Pirzada FA et al. (1978) Experimental myocardial infarction. 14. Accelerated myocardial stiffening related to coronary reperfusion following ischemia. Chest 74: 190-195
19. Braunwald E (1989) Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival: Should the paradigm be expanded? Circulation 79: 441-444
20. Lange RA et al. (1990) Influence of anterograde flow in the infarct artery on the incidence of late potentials after acute myocardial infarction. Am J Cardiol 65: 564-558
21. Sabovic M et al. (1990) Correlation between progressive adsorption of plasminogen to blood clots and their sensitivity to lysis. Thromb Haemost 64: 450-454
22. Madsen JK et al. (1997) Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAM). DANish trial in Acute Myocardial Infarction. Circulation 96: 748-755
23. Erne P et al. (2007) Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction. The SWISSI II randomized controlled trial. JAMA 297: 1985-1991
24. Sirnes PA et al. (1998) Sustained benefit of stenting chronic coronary occlusion: Long-term clinical follow-up of the Stenting in Chronic Coronary Occlusion (SICCO) study. J Am Coll Cardiol 32 305-310
25. Antman EM et al. (2004) ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial Infarction). J Am Coll Cardiol 44:e1-E211
26. Grines CL et al. (2007) Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary stents: A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians Circulation 115: 813-818
27. Cannon CP et al. (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 1495-1504
28. The MIAMI Trial Research Group (1985) Metoprolol in acute myocardial infarction: Mortality. Am J Cardiol 56: 15G-22G
29. The MIAMI Trial Research Group (1985) Metoprolol in acute myocardial infarction: Arrhythmias. Am J Cardiol 56: 35G-38G
30. First International Study of Infarct Survival Collaborative Group (1986) Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 2: 57-66
31. The MIAMI Trial Research Group (1985). Metoprolol in acute myocardial infarction: Enzymetic estimation of infarct size. Am J Cardiol 58: 27G-29G
32. Glamann DB et al. (1991) Beneficial effect of long-term beta blockade after acute myocardial infarction in patients without anterograde flow in the infarct artery. Am J Cardiol 68: 150-154
33. Anderson JR et al. (2007) Persistent coronary occlusion after myocardial infarction, N Engl J Med 356: 1681-1684
34. Hillis LD and Lange RA (2006) Myocardial inferation and the open-artery hypothesis. N Engl J Med 355: 2475-2477
35. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group (1995) ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate In 58,050 patients with suspected acute myocardial infarction. Lancet 345: 669-685
36. Pfeffer MA et al. (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327: 669-677
37. Pfaffer MA et al. (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349: 1893-1906
38. Pfeffer MA et al. (1988) Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med 319: 80-86
39. Montalescot G et al. (2001) Platelet glycoprotein llb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 344: 1895-1903
40. Topoll E.J; GUSTO V Investigators (2001) Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein llb/IIIa inhibition: The GUSTO V randomised trial. Lancet 357: 1905-1914
41. Iwakura, K et al. (2001) Predictive factors for development of the no-reflow phenomenon in patients with reperfused anterior wall acute myocardial infarction. J Am Call Cardiol 38: 472-477
42. Neumann FJ et al. (1998) Effect of glycoprotein llb/llla receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 98: 2695-2701
43. de Lemos JA et al. (2004) Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. JAMA 292: 1307-1316
44. Rosenson RS and Thangney CC (1998) Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction. JAMA 279: 1643-1650
45. Ridker PM et al. (1999) Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 100: 230-235
46. Schartl M et al. (2001) Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation 104: 387-392
47. Egashira K et al. (1994) Reduction in serum cholesterol with pravastatin improves endothellum-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 89: 2519-2524
48. Corti R et al. (2001) Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: A longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation 104: 249-252
49. Iwakura K et al. (2006) Chronic pre-treatment of statins is associated with the reduction of the no-reflow phenomenon in the patients with reperfused acute myocardial infarction. Eur Heart J 27: 534-539
50. Lorenz H et al. (2005) Do statins influence the prognostic impact of non-sustained ventricular tachycardia after ST-elevation myocardial infarction? Eur Heart J 26: 1078-1085
51. [No authors listed] (1983) Risk stratification and survival after myocardial infarction. N Engl J Med 309: 331-336
52. Burns RJ et al. (2002) The relationships of left ventricular election fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. J Am Coll Cardiol 39: 30-36
53. Nelson C and Marwick TH (2005) Clinical decision-making and myocardial viability: Current perspectives. Intern Med J 35: 118-125
54. Tillisch J et al. (1986) Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 314: 884-888
55. Bax JJ et al. (1999) Improvement of left ventricular election fraction, heart failure symptoms and prognosis after revascularization in patients with chronic coronary artery disease and viable myocardium detected by dobutamine stress echocardiography. J Am Coll Cardiol 34: 163-169
56. Allman KC et al. (2002) Myocardial viability testing and impact of revacularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: A meta-analysis. J Am Coll Cardiol 39: 1159-1162
57. Kim RJ et al. (2000) The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 343: 1445-1453
58. Veen G (2006) Early and long-term outcomes of elective stenting of the infarct-related artery in patients with viability in the infarct area: the Viability-Guided Angioplasty after Acute Myocardial Infarction trials (presentation #3417). Presented at the World Congress of Cardiology September 4, Barcelona, Spain
59. Mahmarian JJ et al. (2006) An Initial strategy of intensive medical therapy is comparable to that of coronary revascularization for suppression of scintigraphic ischemia in high-risk but stable survivors of acute myocardial infarction. J Am Coll Cardiol 48: 2458-2467
60. Maddahi J et al. (1986) Noninvasive identification of left main and triple vessell coronary artery disease: Improved accuracy using quantitative analysis of regional myocardial stress distribution and washout of thallium-201. J Am Coll Cardiol 7,53-60
61. Newby LK et al. (2001) Bedside multimarker testing for risk stratification in chest pain units: The chest pain evaluation by creatine kinase-MB, myoglobin, and troponin I (CHECKMATE) study. Circulation 103: 1832-1837
62. Ridker PM (2003) Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107: 363-369
63. Sanchis J et al. (2004) Usefulness of C-reactive protein and left ventricular function for risk assessment in survivors of acute myocardial infarction. Am J Cardiol 94: 766-769
64. Dimitrijevic O et al. (2006) Serial measurements of C-reactive protein after acute myocardial infarction in predicting one-year outcome. Int Heart J 47: 833-842
65. Zairis MN et al. (2002) C-reactive protein levels on admission are associated with response to thrombolysis and prognosis after ST-segment elevation acute myocardial infarction. Am Heart J 144: 782-789
66. Hoffman R et al. (2006) Association of C-reactive protein and myocardial perfusion in patients with ST-elevation acute myocardial infarction. Atherosclerosis 186: 177-183
67. Steg PG et al. (2006) Predischarge C-reactive protein and 1-year outcome after acute coronary syndromes. Am J Med 199: 684-692
68. Ikonomidis I et al. (1999) Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 100: 793-798
69. Hanefeld M et al. (2007) Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: The PIOSTAT Study. J Am Coll Cardiol 49: 290-297
70. Pepys MB et al. (2006) Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 440: 1217-1221
71. Morrow DA et al. (2005) Prognostic value of serial B-type natriuretic peptide testing-during follow-up of patients with unstable coronary artery disease. JAMA 294: 2866-2871
72. de Lemos JA et al. (2001) The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 345: 1014-1021
73. Heeschen C et al. (2004) N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 110: 3206-3212
74. Sarullo FM et al. (2007) Usefulness of N-terminal pro-B-type natriuretic peptide levels in predicting residual myocardial ischemia in patients with ST elevation acute myocardial infarction. Minerva Cardioangiol 55: 149-155